Squamous cell carcinoma - Kansera Hucreya Squamous
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Squamous cell carcinoma well differentiated - Keratozek aktînîkî ya cîran tê dîtin.
References
Squamous cell carcinoma (SCC) li Dewletên Yekbûyî, piştî basal cell carcinoma , duyemîn kansera çermê ya herî gelemperî ye. Ew bi gelemperî ji birînên pêşkanserê bi navê actinic keratosis dest pê dike, û dikare li beşên din ên laş belav bibe. Sedema sereke gihandina tîrêjên ultraviolet (UV) yên rojê ye, ku bi demê re kom dibe. Dermankirin bi gelemperî rakirina neştergerî pêk tîne, nemaze ji bo SCC li ser ser û stûyê. Terapiya radyasyonê ji bo nexweşên pîr an jî yên ku nikarin emeliyat bikin vebijarkek e. Immunosuppression rîska SCC zêde dike. Her çend kêm kêm be jî, SCC dikare belav bibe, nemaze di nexweşên xwedan pergalên parastinê yên qels de. Kontrolên birêkûpêk û parastina tavê ji bo kesên bi SCC re girîng in.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) di nav mirovan de kansera duyemîn a herî berbelav e, û hejmara wê her ku diçe zêde dibe. Her çend CSCC bi gelemperî tevgerek klînîkî ya dilşewat nîşan dide, ew dikare hem herêmî û hem jî li beşên din ên laş belav bibe. Zanyaran rêyên taybetî yên ku di pêşkeftina CSCC de beşdar bûne nas kirine, ku rê li ber dermankirinên nû vedike. Hejmara zêde ya mutasyon û xetera zêde ya di nexweşên immunosuppressed de pêşveçûna immunoterapiyê kiriye. Ev vekolîn li kokên genetîkî yên CSCC û dermankirinên herî paşîn ên ku molekulên taybetî û pergala berevaniyê hedef digirin dinêre.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Nîşanî û dermankirin
#Dermoscopy
#Skin biopsy